Lamivudine + Tenofovir Disoproxil
Fixed-dose combination
This page lists brands whose active-ingredient set is exactly the combination below. It is identity information only — a fixed-dose combination is not the same product as its single ingredients, and the brand names are not interchangeable across markets.
Not medical advice. Check the pack and the exact composition before comparing products; ask a pharmacist if unsure.
Active ingredients
- Lamivudine
lamivudine - Tenofovir Disoproxil
tenofovir-disoproxil
Brands with this exact combination
| Brand | Dose | Manufacturer |
|---|---|---|
| Lamivudine 300mg / Tenofovir disoproxil 245mg tabletsESGB | 300 mg / 245 mg | Cipla EU Ltd |
| CIMDUOUS | 300 mg | Viatris Specialty LLC |
| Lamivudine and Tenofovir Disoproxil FumarateUS | 300 mg | Viatris Specialty LLC |
| LAMIVUDINA/TENOFOVIR DISOPROXILO CIPLAES | 300 mg / 245 mg | Cipla Europe |
| lamivudina + tenofovirES | 300 mg / 245 mg | Cipla Europe |
Same combination in other markets
No product with this combination is recorded in the other covered markets yet.
Only the main ingredient is the same — this is NOT the same fixed-dose combination. View the main ingredient
See warnings for these ingredients
Source & licence: built from the same regulator data as the ingredient pages (openFDA, dm+d, CIMA, COFEPRIS, PBS/TGA, Health Canada DPD, NHSA). Facts only; see the licence register.